CA9 Antibodies

Structure of CA9

CA9 is a transmembrane protein with a molecular weight of approximately 54-58 kDa. Its size may vary slightly depending on the degree of glycosylation modification. This protein is composed of 459 amino acids and contains an extracellular catalytic domain, a transmembrane region and an intracellular short tail. The active center of CA9 has a zinc ion binding site, which is the key to its catalytic reversible hydration reaction of carbon dioxide. Its extracellular region contains conserved carbonic anhydrase characteristic sequences and stabilizes the spatial conformation through disulfide bonds. The expression of CA9 is significantly upregulated mainly in solid tumors, especially showing high specificity in clear cell renal cell carcinoma. Its protein structure and function make it an important research object for tumor-targeted therapy.

Fig. 1 Linkage disequilibrium (LD) and haplotype block structure of the CA9 gene.¹

Key structural properties of CA9:

• Extracellular carbonic anhydrase domain
• Transmembrane anchor regions maintain protein membrane localization
• Intracellular short tails are involved in signal transduction

Functions of CA9

The main function of the CA9 gene is to regulate cell pH and promote tumor adaptation to hypoxic environments. In addition, it is also involved in various pathological processes such as cell proliferation, migration and metastasis.

The activity of CA9 depends on zinc ion cofactors. Its enzymatic kinetic characteristics are characterized by high catalytic efficiency and adaptability to acidic environments, playing a key role in tumor metabolic reprogramming.

Applications of CA9 and CA9 Antibody in Literature

1. Yin, Lingdi, et al. "CA9-related acidic microenvironment mediates CD8+ T cell related immunosuppression in pancreatic cancer." Frontiers in Oncology 11 (2022): 832315. https://doi.org/10.3389/fonc.2021.832315

This study integrated multi-omics data and found that pancreatic cancer cells highly express the CA9 gene. It inhibits CD8⁺T cell infiltration by mediating an acidic microenvironment, promotes immune escape, and affects patient prognosis, providing a new direction for immunotargeted therapy.

2. Guan, Chenyu, et al. "CA9 transcriptional expression determines prognosis and tumour grade in tongue squamous cell carcinoma patients." Journal of cellular and molecular medicine 24.10 (2020): 5832-5841. https://doi.org/10.1111/jcmm.15252

This study, based on TCGA data analysis, found that CA9 is highly expressed in tongue squamous cell carcinoma and is associated with prognosis and tumor grade. CA9 promotes tumor progression by regulating cell differentiation, apoptosis, hypoxia and signaling pathways such as PI3K/AKT/mTOR, but has no significant association with immune infiltration.

3. Xu, Jiatong, et al. "CA9 silencing promotes mitochondrial biogenesis, increases putrescine toxicity and decreases cell motility to suppress ccRCC progression." International journal of molecular sciences 21.16 (2020): 5939. https://doi.org/10.3390/ijms21165939

This study confirmed that CA9 is highly expressed in clear cell renal cell carcinoma. Knockdown of CA9 can inhibit proliferation by up-regulating ARG2 and accumulating putrescine, and reduce migration by down-regulating extracellular matrix interaction and amino acid transport, indicating that CA9 is a potential therapeutic target.

4. Hudson, Amanda L., et al. "CA9, CYFIP2 and LGALS3BP—A Novel Biomarker Panel to Aid Prognostication in Glioma." Cancers 16.5 (2024): 1069. https://doi.org/10.3390/cancers16051069

This study aims to discover prognostic biomarkers for glioma progression. Verification revealed that CA9, CYFIP2 and LGALS3BP are associated with progression, and a three-protein combination panel was constructed, which can effectively distinguish the long and short survival periods of patients and has significant clinical potential.

5. Zhao, Kunming, et al. "LncRNA ZNF674-AS1 drives cell growth and inhibits cisplatin-induced pyroptosis via up-regulating CA9 in neuroblastoma." Cell Death & Disease 15.1 (2024): 5. https://doi.org/10.1038/s41419-023-06394-8

This study reveals that lncRNA ZNF674-AS1 stabilizes CA9 mRNA by binding to IGF2BP3, thereby upregulating CA9 expression, promoting the proliferation of neuroblastoma and cisplatin resistance. Targeting this axis can provide a new treatment strategy.

Creative Biolabs: CA9 Antibodies for Research

Creative Biolabs specializes in the production of high-quality CA9 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom CA9 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CA9 antibodies, custom preparations, or technical support, contact us at email.